Atezolizumab

Management of biliary tract cancers with targeted therapies 4:50
Management of biliary tract cancers with targeted therapies
Ghassan Abou-Alfa • 20 Jan 2023
The impact of immunotherapy and checkpoint inhibition in treating HCC 1:10
The impact of immunotherapy and checkpoint inhibition in treating HCC
Changhoon Yoo • 19 Jan 2023
Recent immunotherapy advances in HCC management 1:57
Recent immunotherapy advances in HCC management
Richard Finn • 20 Jan 2023
STELLAR-303: XL092 with atezolizumab or regorafenib in patients with mCRC 2:32
STELLAR-303: XL092 with atezolizumab or regorafenib in patients with mCRC
J. Randolph Hecht • 20 Jan 2023
Optimizing HCC treatment with predicative biomarkers 1:07
Optimizing HCC treatment with predicative biomarkers
Changhoon Yoo • 19 Jan 2023
STELLAR-303: XL092, a novel TKI, in pre-treated, MMS/MSI-low colorectal cancer 2:30
STELLAR-303: XL092, a novel TKI, in pre-treated, MMS/MSI-low colorectal cancer
Anwaar Saeed • 21 Jan 2023
Cabozantinib in patients with HCC refractory to checkpoint inhibitors 1:36
Cabozantinib in patients with HCC refractory to checkpoint inhibitors
Stephen Lam Chan • 19 Jan 2023
Overcoming resistance to ICIs in biliary tract cancers 1:04
Overcoming resistance to ICIs in biliary tract cancers
Rachna Shroff • 19 Jan 2023
Phase II trial of cabozantinib for patients with HCC previously treated with IO 2:58
Phase II trial of cabozantinib for patients with HCC previously treated with IO
Stephen L. Chan • 5 Dec 2022
Improving guidance on choice of first-line therapy for patients with HCC 1:09
Improving guidance on choice of first-line therapy for patients with HCC
Mara Persano • 1 Dec 2022
Real-world outcomes of patients with HCC treated with lenvatinib vs. atezolizumab plus bevacizumab 4:03
Real-world outcomes of patients with HCC treated with lenvatinib vs. atezolizumab plus bevacizumab
Mara Persano • 1 Dec 2022
Effectiveness of ICIs in the neoadjuvant and post-neoadjuvant breast cancer setting 1:59
Effectiveness of ICIs in the neoadjuvant and post-neoadjuvant breast cancer setting
Lajos Pusztai • 8 Dec 2022
ALICE: atezolizumab + immunogenic chemotherapy in metastatic TNBC 4:38
ALICE: atezolizumab + immunogenic chemotherapy in metastatic TNBC
Jon Amund Kyte • 8 Dec 2022
NeoMono: mono atezolizumab window followed by atezolizumab – CTX vs atezolizumab – CTX 3:57
NeoMono: mono atezolizumab window followed by atezolizumab – CTX vs atezolizumab – CTX
Hans-Christian Kolberg • 7 Dec 2022
SOLTI-1503 PROMETEO: T-VEC + atezolizumab in patients with residual BC after neoadjuvant chemo 3:06
SOLTI-1503 PROMETEO: T-VEC + atezolizumab in patients with residual BC after neoadjuvant chemo
Tomás Pascual • 6 Dec 2022
Checkpoint inhibition in hepatocellular carcinoma 4:53
Checkpoint inhibition in hepatocellular carcinoma
Ghassan Abou-Alfa • 23 Nov 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals